Gunta Purkalne

Riga, RIX, LV 
Riga, RIX, LV 

Overview

Gunta Purkalne practices practicing medicine in Riga, Latvia.

Their clinical expertise encompasses Colorectal Cancer, Triple-Negative Breast Cancer, Breast Cancer, and Lung Cancer.

They are actively involved in clinical research, co-authoring 19 peer reviewed articles and participating in 2 clinical trials.

Locations

Riga, RIX, Latvia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Carboplatin, Etoposide, Atezolizumab
Study Phase: Phase 2
A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Patients With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Patients With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drugs: Bevacizumab, HD204, Carboplatin, Paclitaxel
Study Phase: Phase 3
View 1 Less Clinical Trial

19 Total Publications

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer - single hospital experience.
Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer - single hospital experience.
Journal: Hereditary cancer in clinical practice
Published: July 21, 2022

Frequently Asked Questions about Gunta Purkalne

Is Gunta Purkalne a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Gunta Purkalne is classified as an Experienced expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Gunta Purkalne participate in research or clinical trials?

Yes. Gunta Purkalne has published 19 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Gunta Purkalne's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Purkalne's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile